FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322009021> ?p ?o ?g. }

• W4322009021 abstract "Abstract Background At the end of 2021, the European Medicines Agency (EMA) expanded its approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the treatment of COVID-19 patients with elevated soluble urokinase plasminogen activator receptor (suPAR). However, the role of Anakinra in COVID-19 remains unanswered, especially in patients receiving different forms of respiratory support. Therefore, the objective of this systematic review is to assess the safety and effects of Anakinra compared to placebo or standard care alone on clinical outcomes in adult hospitalized patients with SARS-CoV-2 infection. Methods We searched the Cochrane COVID-19 Study Register (comprising MEDLINE, Embase, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, medRxiv, and the Cochrane Central Register of Controlled Trials (CCSR)) and the WHO COVID-19 Global literature on coronavirus disease database to identify completed and ongoing studies from inception of each database to December 13, 2021. Since then, we monitored new published studies weekly up to June 30, 2022 using the CCSR. We included RCTs comparing treatment with Anakinra to placebo or standard care alone in adult hospitalized patients with SARS-CoV-2 infection. Results We included five RCTs with 1,627 patients ( n Anakinra = 888, n control = 739, mean age 59.63 years, 64% male). Random-effects meta-analysis was used to pool data. We found that Anakinra makes little or no difference to all-cause mortality at up to day 28 compared to placebo or standard care alone (RR 0.96 , 95% CI 0.64–1.45; RD 9 fewer per 1000, 95% CI 84 fewer to 104 more; 4 studies, 1593 participants; I 2 = 49%; low certainty of evidence). Conclusions Anakinra has no effect on adult hospitalized patients with SARS-CoV-2 infection regarding mortality, clinical improvement and worsening as well as on safety outcomes compared to placebo or standard care alone. Trial Registration : PROSPERO Registration Number: CRD42021257552." @default.
• W4322009021 created "2023-02-26" @default.
• W4322009021 creator A5019092049 @default.
• W4322009021 creator A5025241260 @default.
• W4322009021 creator A5040990793 @default.
• W4322009021 creator A5066886079 @default.
• W4322009021 creator A5084600026 @default.
• W4322009021 creator A5085750813 @default.
• W4322009021 date "2023-02-25" @default.
• W4322009021 modified "2023-10-05" @default.
• W4322009021 title "Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis" @default.
• W4322009021 cites W2125435699 @default.
• W4322009021 cites W2560438049 @default.
• W4322009021 cites W2970684805 @default.
• W4322009021 cites W3014214532 @default.
• W4322009021 cites W3032677363 @default.
• W4322009021 cites W3042529211 @default.
• W4322009021 cites W3046768463 @default.
• W4322009021 cites W3049269555 @default.
• W4322009021 cites W3049387801 @default.
• W4322009021 cites W3093383252 @default.
• W4322009021 cites W3095131550 @default.
• W4322009021 cites W3110759332 @default.
• W4322009021 cites W3117652431 @default.
• W4322009021 cites W3124292577 @default.
• W4322009021 cites W3126231175 @default.
• W4322009021 cites W3127398218 @default.
• W4322009021 cites W3133691270 @default.
• W4322009021 cites W3160676231 @default.
• W4322009021 cites W3162843880 @default.
• W4322009021 cites W3163138311 @default.
• W4322009021 cites W3188840229 @default.
• W4322009021 cites W3198379317 @default.
• W4322009021 cites W3202535722 @default.
• W4322009021 cites W3211941980 @default.
• W4322009021 cites W4210512034 @default.
• W4322009021 cites W4226157238 @default.
• W4322009021 cites W4319433244 @default.
• W4322009021 doi "https://doi.org/10.1186/s40001-023-01072-z" @default.
• W4322009021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36841793" @default.
• W4322009021 hasPublicationYear "2023" @default.
• W4322009021 type Work @default.
• W4322009021 citedByCount "4" @default.
• W4322009021 countsByYear W43220090212023 @default.
• W4322009021 crossrefType "journal-article" @default.
• W4322009021 hasAuthorship W4322009021A5019092049 @default.
• W4322009021 hasAuthorship W4322009021A5025241260 @default.
• W4322009021 hasAuthorship W4322009021A5040990793 @default.
• W4322009021 hasAuthorship W4322009021A5066886079 @default.
• W4322009021 hasAuthorship W4322009021A5084600026 @default.
• W4322009021 hasAuthorship W4322009021A5085750813 @default.
• W4322009021 hasBestOaLocation W43220090211 @default.
• W4322009021 hasConcept C126322002 @default.
• W4322009021 hasConcept C142724271 @default.
• W4322009021 hasConcept C168563851 @default.
• W4322009021 hasConcept C17744445 @default.
• W4322009021 hasConcept C189708586 @default.
• W4322009021 hasConcept C199539241 @default.
• W4322009021 hasConcept C204787440 @default.
• W4322009021 hasConcept C27081682 @default.
• W4322009021 hasConcept C2779134260 @default.
• W4322009021 hasConcept C2779473830 @default.
• W4322009021 hasConcept C2781228260 @default.
• W4322009021 hasConcept C535046627 @default.
• W4322009021 hasConcept C71924100 @default.
• W4322009021 hasConcept C95190672 @default.
• W4322009021 hasConceptScore W4322009021C126322002 @default.
• W4322009021 hasConceptScore W4322009021C142724271 @default.
• W4322009021 hasConceptScore W4322009021C168563851 @default.
• W4322009021 hasConceptScore W4322009021C17744445 @default.
• W4322009021 hasConceptScore W4322009021C189708586 @default.
• W4322009021 hasConceptScore W4322009021C199539241 @default.
• W4322009021 hasConceptScore W4322009021C204787440 @default.
• W4322009021 hasConceptScore W4322009021C27081682 @default.
• W4322009021 hasConceptScore W4322009021C2779134260 @default.
• W4322009021 hasConceptScore W4322009021C2779473830 @default.
• W4322009021 hasConceptScore W4322009021C2781228260 @default.
• W4322009021 hasConceptScore W4322009021C535046627 @default.
• W4322009021 hasConceptScore W4322009021C71924100 @default.
• W4322009021 hasConceptScore W4322009021C95190672 @default.
• W4322009021 hasFunder F4320321114 @default.
• W4322009021 hasFunder F4320324232 @default.
• W4322009021 hasIssue "1" @default.
• W4322009021 hasLocation W43220090211 @default.
• W4322009021 hasLocation W43220090212 @default.
• W4322009021 hasLocation W43220090213 @default.
• W4322009021 hasOpenAccess W4322009021 @default.
• W4322009021 hasPrimaryLocation W43220090211 @default.
• W4322009021 hasRelatedWork W1967911880 @default.
• W4322009021 hasRelatedWork W2066421181 @default.
• W4322009021 hasRelatedWork W2098995101 @default.
• W4322009021 hasRelatedWork W2181724637 @default.
• W4322009021 hasRelatedWork W2550419422 @default.
• W4322009021 hasRelatedWork W3027459656 @default.
• W4322009021 hasRelatedWork W4210720822 @default.
• W4322009021 hasRelatedWork W4281920545 @default.
• W4322009021 hasRelatedWork W4285503101 @default.
• W4322009021 hasRelatedWork W4315436681 @default.
• W4322009021 hasVolume "28" @default.
• W4322009021 isParatext "false" @default.

• next